Liposomal formulations of combinational antibiotics
Researchers at Purdue University have developed a new liposomal formulation of combinational antibiotics for the treatment of respiratory infections. This new formulation incorporates two synergistic antibiotics to enable maximum bacteria killing against resistant pathogens while significantly reducing irritation to the respiratory tract.
Liposomal formulations have been developed for single drugs such as ciprofloxacin but not for combinational antibiotics. Liposomal formulations have shown significantly less irritation to the respiratory tract and much better safety in previous clinical trials. Developing liposomal formulations for combinational antibiotics might be beneficial for the treatment of respiratory infections.